Mercury Labs

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE947G01011
NSEID:
BSEID: 538964
View on BSE

INR

753.10

-14.9 (-1.94%)

BSENSE

Sep 01, 03:30 PM

BSE+NSE Vol: 8

{
  "main_header": {
    "sid": 287757,
    "name": "Mercury Labs",
    "stock_name": "Mercury Labs",
    "full_name": "Mercury Laboratories Ltd",
    "name_url": "stocks-analysis/mercury-labs",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "753.10",
    "chg": -14.9,
    "chgp": "-1.94%",
    "dir": -1,
    "prev_price": "768.00",
    "mcapval": "92.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 538964,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE947G01011",
    "curr_date": "Sep 01, 03:30 PM",
    "curr_time": "05:06 AM",
    "last_traded_at": "Sep 01, 03:30 PM IST",
    "bse_nse_vol": "8 ",
    "exc_status": "Active",
    "traded_date": "Sep 01, 2026",
    "traded_date_str": "2026 09 01",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/mercury-labs-287757-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Mercury Laboratories Ltd Downgraded to Strong Sell Amid Weak Technicals and Financials",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/mercury-laboratories-ltd-downgraded-to-strong-sell-amid-weak-technicals-and-financials-4159076",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/MercuryLaborato_mojoScore_4159076.png",
        "date": "2026-08-18 08:34:48",
        "description": "Mercury Laboratories Ltd has been downgraded from a Sell to a Strong Sell rating by MarketsMOJO as of 17 Aug 2026, reflecting deteriorating technical indicators, disappointing financial trends, and persistent underperformance relative to benchmarks. The micro-cap pharmaceutical company faces significant headwinds across quality, valuation, financial trend, and technical parameters, prompting a reassessment of its investment appeal."
      },
      {
        "title": "Mercury Laboratories Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/mercury-laboratories-ltd-is-rated-sell-4145177",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/MercuryLaborato_mojoScore_4145177.png",
        "date": "2026-08-10 10:10:22",
        "description": "Mercury Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 28 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 August 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "Mercury Laboratories Ltd Falls 4.67%: Quality Upgrade Amidst Financial Strain",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/mercury-laboratories-ltd-falls-467-quality-upgrade-amidst-financial-strain-4132161",
        "imagepath": "",
        "date": "2026-08-02 10:00:58",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>27 Jul:</strong> Sharp 3.99% drop in stock price amid strong Sensex rally</p>\n                    <p><strong>28 Jul:</strong> Quality grade upgraded from below average to average; Mojo rating raised to Sell</p>\n                    <p><strong>29 Jul:</strong> Quarterly results reveal weak financial trend and lowest quarterly EPS</p>\n                    <p><strong>30-31 Jul:</strong> Minor recovery attempts with stable prices despite positive Sensex moves</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.835.00</div></div>\n                    <div class=\"sta..."
      },
      {
        "title": "Mercury Laboratories Ltd Upgraded to Sell on Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/mercury-laboratories-ltd-upgraded-to-sell-on-mixed-financial-and-technical-signals-4125298",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/MercuryLaborato_mojoScore_4125298.png",
        "date": "2026-07-29 08:19:11",
        "description": "Mercury Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 28 July 2026, reflecting a nuanced shift in its financial, quality, valuation, and technical parameters. Despite ongoing challenges in quarterly financial performance, the company’s quality metrics have improved to an average grade, while technical indicators suggest a mildly bearish outlook. This article analyses the key factors driving this rating change and what it means for investors navigating the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Mercury Laboratories Ltd Quality Grade Upgrade Signals Mixed Business Fundamentals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/mercury-laboratories-ltd-quality-grade-upgrade-signals-mixed-business-fundamentals-4124899",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/MercuryLaborato_qualitydot_4124899.png",
        "date": "2026-07-29 08:00:09",
        "description": "Mercury Laboratories Ltd has seen its quality grade improve from below average to average, reflecting a nuanced shift in its business fundamentals. While certain key metrics such as return on capital employed (ROCE) and return on equity (ROE) show moderate strength, other indicators like earnings growth and debt levels present a more complex picture for investors navigating the pharmaceuticals and biotechnology sector."
      },
      {
        "title": "Are Mercury Laboratories Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-mercury-laboratories-ltd-latest-results-good-or-bad-4121563",
        "imagepath": "",
        "date": "2026-07-26 19:12:06",
        "description": "Mercury Laboratories Ltd's latest financial results for Q1 FY27 indicate significant operational challenges. The company reported net sales of ₹15.96 crores, reflecting a sequential decline of 21.92% from ₹20.44 crores in Q4 FY26, marking the lowest quarterly sales figure in recent history. Year-on-year, this represents a contraction of 12.02% from ₹18.14 crores in Q1 FY26. \n\nThe operating profit margins have also faced considerable pressure, compressing to 7.46% from 13.01% in the same quarter last year, which indicates a decline of 555 basis points. Similarly, net profit margins fell to 1.88% from 5.35% year-on-year, highlighting a substantial drop in profitability. The net profit for the quarter was recorded at ₹0.30 crores, down 69.07% from ₹1.23 crores in Q4 FY26, further underscoring the company's struggle with profitability amid rising costs and stagnant revenue growth.\n\nThe company's financial perfo..."
      },
      {
        "title": "Mercury Laboratories Q1 FY27: Profit Plunges 69% as Revenue Decline Deepens Operational Woes",
        "link": "https://www.marketsmojo.com/news/result-analysis/mercury-laboratories-q1-fy27-profit-plunges-69-as-revenue-decline-deepens-operational-woes-4120839",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/MercuryLaborato_quaterlyResult_4120839.png",
        "date": "2026-07-25 18:30:43",
        "description": "Mercury Laboratories Ltd., a micro-cap pharmaceutical manufacturer with a market capitalisation of ₹97.00 crores, reported deeply disappointing results for Q1 FY27, with net profit collapsing 69.07% quarter-on-quarter to ₹0.30 crores from ₹0.97 crores in the previous quarter. The stock, trading at ₹835.00, has declined 4.02% over the past year, significantly underperforming its pharmaceuticals sector peers who gained 11.43% during the same period."
      },
      {
        "title": "Mercury Laboratories Ltd Downgraded to Strong Sell Amid Weak Fundamentals and Bearish Technicals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/mercury-laboratories-ltd-downgraded-to-strong-sell-amid-weak-fundamentals-and-bearish-technicals-4117208",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/MercuryLaborato_mojoScore_4117208.png",
        "date": "2026-07-23 08:18:20",
        "description": "Mercury Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 22 July 2026. This adjustment reflects a combination of deteriorating technical indicators, stagnant financial performance, and weak long-term fundamentals, despite some attractive valuation metrics. The downgrade signals caution for investors amid mixed signals from the company’s operational and market trends."
      },
      {
        "title": "When is the next results date for Mercury Laboratories Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-mercury-laboratories-ltd-4106749",
        "imagepath": "",
        "date": "2026-07-17 23:16:32",
        "description": "The next results date for Mercury Laboratories Ltd is scheduled for 25 July 2026...."
      }
    ],
    "total": 156,
    "sid": "287757",
    "stock_news_url": "https://www.marketsmojo.com/news/mercury-laboratories-287757"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "27-Aug-2026",
      "details": "Newspaper publication regarding 45th AGM to be held on September 28 2026 is attached",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
      "datetime": "21-Aug-2026",
      "details": "Intimation regarding appointment of Mr. Sunil Sharma and resignation of Ms. Seema Salvi as HOD injectable",
      "source": "BSE"
    },
    {
      "caption": "Communication To Shareholders - Intimation On Tax Deduction On Dividend",
      "datetime": "20-Aug-2026",
      "details": "Communication to Shareholders on TDS on the dividend for the FY 25-26 is attached",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Mercury Laboratories Ltd has declared <strong>35%</strong> dividend, ex-date: 21 Sep 26",
          "dt": "2026-09-21",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Mercury Laboratories Ltd Downgraded to Strong Sell Amid Weak Technicals and Financials

2026-08-18 08:34:48

Mercury Laboratories Ltd has been downgraded from a Sell to a Strong Sell rating by MarketsMOJO as of 17 Aug 2026, reflecting deteriorating technical indicators, disappointing financial trends, and persistent underperformance relative to benchmarks. The micro-cap pharmaceutical company faces significant headwinds across quality, valuation, financial trend, and technical parameters, prompting a reassessment of its investment appeal.

Read full news article

Mercury Laboratories Ltd is Rated Sell

2026-08-10 10:10:22

Mercury Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 28 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 August 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

Mercury Laboratories Ltd Falls 4.67%: Quality Upgrade Amidst Financial Strain

2026-08-02 10:00:58

Key Events This Week

27 Jul: Sharp 3.99% drop in stock price amid strong Sensex rally

28 Jul: Quality grade upgraded from below average to average; Mojo rating raised to Sell

29 Jul: Quarterly results reveal weak financial trend and lowest quarterly EPS

30-31 Jul: Minor recovery attempts with stable prices despite positive Sensex moves

Week Open

Rs.835.00

Read full news article

Mercury Laboratories Ltd Upgraded to Sell on Mixed Financial and Technical Signals

2026-07-29 08:19:11

Mercury Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 28 July 2026, reflecting a nuanced shift in its financial, quality, valuation, and technical parameters. Despite ongoing challenges in quarterly financial performance, the company’s quality metrics have improved to an average grade, while technical indicators suggest a mildly bearish outlook. This article analyses the key factors driving this rating change and what it means for investors navigating the Pharmaceuticals & Biotechnology sector.

Read full news article

Mercury Laboratories Ltd Quality Grade Upgrade Signals Mixed Business Fundamentals

2026-07-29 08:00:09

Mercury Laboratories Ltd has seen its quality grade improve from below average to average, reflecting a nuanced shift in its business fundamentals. While certain key metrics such as return on capital employed (ROCE) and return on equity (ROE) show moderate strength, other indicators like earnings growth and debt levels present a more complex picture for investors navigating the pharmaceuticals and biotechnology sector.

Read full news article

Are Mercury Laboratories Ltd latest results good or bad?

2026-07-26 19:12:06

Mercury Laboratories Ltd's latest financial results for Q1 FY27 indicate significant operational challenges. The company reported net sales of ₹15.96 crores, reflecting a sequential decline of 21.92% from ₹20.44 crores in Q4 FY26, marking the lowest quarterly sales figure in recent history. Year-on-year, this represents a contraction of 12.02% from ₹18.14 crores in Q1 FY26. The operating profit margins have also faced considerable pressure, compressing to 7.46% from 13.01% in the same quarter last year, which indicates a decline of 555 basis points. Similarly, net profit margins fell to 1.88% from 5.35% year-on-year, highlighting a substantial drop in profitability. The net profit for the quarter was recorded at ₹0.30 crores, down 69.07% from ₹1.23 crores in Q4 FY26, further underscoring the company's struggle with profitability amid rising costs and stagnant revenue growth. The company's financial perfo...

Read full news article

Mercury Laboratories Q1 FY27: Profit Plunges 69% as Revenue Decline Deepens Operational Woes

2026-07-25 18:30:43

Mercury Laboratories Ltd., a micro-cap pharmaceutical manufacturer with a market capitalisation of ₹97.00 crores, reported deeply disappointing results for Q1 FY27, with net profit collapsing 69.07% quarter-on-quarter to ₹0.30 crores from ₹0.97 crores in the previous quarter. The stock, trading at ₹835.00, has declined 4.02% over the past year, significantly underperforming its pharmaceuticals sector peers who gained 11.43% during the same period.

Read full news article

Mercury Laboratories Ltd Downgraded to Strong Sell Amid Weak Fundamentals and Bearish Technicals

2026-07-23 08:18:20

Mercury Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 22 July 2026. This adjustment reflects a combination of deteriorating technical indicators, stagnant financial performance, and weak long-term fundamentals, despite some attractive valuation metrics. The downgrade signals caution for investors amid mixed signals from the company’s operational and market trends.